Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


New guideline on cancer medicines

Written by | 8 Feb 2013 | All Medical News

EMA Highlights by Eoghan McNeill – The EMA has published revised guidelines on the evaluation of anti-cancer medicines to take account of advances in research and new therapeutic options which have emerged in recent years.

The document contains guidance on all stages of clinical drug development for treatment of cancer. Alongside conventional aims such as defining the proper doses and schedule for a medicine, the guideline highlights the importance of identifying the target population during the development.

The new recommendation, which comes into effect in July, has been updated to include advice on the use of biomarkers as an integrated part of the development of medicines; combination-therapy studies; and the choice of endpoints in confirmatory trials.

It explains how the use of biomarkers throughout non-clinical and clinical development can help identify patients with an increased likelihood to respond favourably to treatment.

According to the new guideline, confirmatory trials should demonstrate that the product under investigation provides clinical benefit. “From both a clinical and a methodological perspective, the most persuasive outcome of a clinical trial is the demonstration of favourable effects on overall survival,” the EMA said.

Prolonged progression-free survival and disease-free survival are also considered to be of benefit to the patient, the regulator says. The guideline describes how to select the appropriate endpoints for confirmatory studies.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.